The pricing applies to an underwritten public offering of 10,526,000 shares of its common stock at a price of $1.90 per share. The gross proceeds of the company’s offerings are expected to be approximately $20 million before underwriting discounts, commissions and estimated offering expenses.
EyePoint Pharmaceuticals gave underwriters a 30-day purchase option for up to an additional 1,578,975 shares of common stock at the public offering price.
The closing of the offering is expected to occur April 1 subject to the satisfaction of closing conditions.
More articles on supply chain:
ASC supply chain tip of the day: Clean up inconsistencies
Are you a materials manager or managed by your materials?
SIS named No. 1 ASC EHR vendor for 4th year straight — 3 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
